Seres Therapeutics, Inc. Restructuring and Related Cost, Number of Positions Eliminated
Seres Therapeutics, Inc. (MCRB) had Restructuring and Related Cost, Number of Positions Eliminated of 160 Employee as of 2023-11-02, per its 10-K filed 2026-03-12.
Financial Statements › Notes
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2026-03-12
- 2023-11-02: Restructuring and Related Cost, Number of Positions Eliminated 160.00 Employee.
- 2023-10-29: Restructuring and Related Cost, Number of Positions Eliminated 160.00 Employee.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated |
|---|---|
| 2023-11-02 | 160.00 Employee 10-K · filed 2026-03-12 |
| 2023-10-29 | 160.00 Employee 8-K · filed 2024-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |